Liu H, Lv HG, Zhang R. Variant of Guillain-Barré syndrome with anti-sulfatide antibody positivity and spinal cord involvement: A case report. World J Clin Cases 2023; 11(26): 6274-6279 [PMID: 37731563 DOI: 10.12998/wjcc.v11.i26.6274]
Corresponding Author of This Article
Rong Zhang, Doctor, Doctor, Department of Neurology, The First People's Hospital of Shizuishan City, No. 1 Kangle Road, Huinong District, Shizuishan 753200, Ningxia Hui Autonomous Region, China. zhangrong1201@outlook.com
Research Domain of This Article
Clinical Neurology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 16, 2023; 11(26): 6274-6279 Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6274
Variant of Guillain-Barré syndrome with anti-sulfatide antibody positivity and spinal cord involvement: A case report
Hua Liu, Hui-Gang Lv, Rong Zhang
Hua Liu, Hui-Gang Lv, Department of Neurology, Yixing Hospital of Traditional Chinese Medicine, Yixing 214200, Jiangsu Province, China
Rong Zhang, Department of Neurology, The First People's Hospital of Shizuishan City, Shizuishan 753200, Ningxia Hui Autonomous Region, China
Author contributions: Liu H and Lv HG examined, evaluated the patient and drafted the manuscript; Zhang R participated in the design of the case-report and helped to draft the manuscript; All authors read and approved the final submission.
Supported byYixing Administration of Traditional Chinese Medicine, No. yxfc03.
Informed consent statement: Written informed consent was obtained from the patient after treatment for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rong Zhang, Doctor, Doctor, Department of Neurology, The First People's Hospital of Shizuishan City, No. 1 Kangle Road, Huinong District, Shizuishan 753200, Ningxia Hui Autonomous Region, China. zhangrong1201@outlook.com
Received: June 6, 2023 Peer-review started: June 6, 2023 First decision: July 17, 2023 Revised: August 8, 2023 Accepted: August 17, 2023 Article in press: August 17, 2023 Published online: September 16, 2023 Processing time: 93 Days and 20.3 Hours
Core Tip
Core Tip: Guillain-Barré syndrome (GBS) is an autoimmune-mediated acute polyneurogenic neuropathy. The clinical presentation of GBS is characterized by an acute onset, symmetric limb weakness, sensory disturbances, extraocular muscle paralysis, ataxia, diminished tendon reflexes, hypotonia, abdominal distention, constipation, and urinary retention following autonomic nerve damage. In recent years, anti-sulfatide antibody positivity has been increasingly noted in GBS cases, with varying clinical symptoms; thus, these antibodies have become crucial for the diagnosis of GBS. Here, we report the case of a patient who presented with signs and symptoms of spinal cord involvement and was diagnosed with anti-sulfatide antibody-positive GBS combined with spinal cord involvement, which is relatively rare in clinical practice; the symptoms improved after receiving combined treatment with intravenous human immunoglobulin and methylprednisolone pulse therapy.